NeoStem to Host Key Opinion Leader Event Webcast on

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
NeoStem to Host Key Opinion Leader Event Webcast on December 1, 2014

NEW YORK, Nov. 26, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq: NBS ), a biopharmaceutical company developing novel cell based therapeutics, announced today that it will host a Key Opinion Leader event webcast on Monday, December 1, 2014 from 4:30 to 5:30 PM EST.

The webcast will feature a presentation by Timothy Henry, MD, Director of Cardiology at the Cedars-Sinai Heart Institute, who will discuss the significance of the Phase 2 PreSERVE AMI (or acute myocardial infarction) clinical trial, the results of which were previously announced on November 17 th . ( http://www.neostem.com/media/press-releases/n...erve-data/ ) Dr. Henry is an internationally recognized expert in the treatment of patients with refractory angina and acute myocardial infarction, with a focus on stem cell therapies. Before joining Cedars-Sinai, Dr. Henry was the Director of Research at the Minneapolis Heart Institute Foundation, at Abbott Northwestern Hospital in Minneapolis and at Hennepin County Medical Center, Minneapolis, as Director of Interventional Cardiology and Director of Cardiac Catheterization Laboratory. Dr. Henry has co-authored nearly 250 manuscripts and book chapters in prominent peer reviewed journals including Circulation Research , Journal of the American Medical Association , Lancet and European Heart Journal . Dr. Henry has served as editor and reviewer for several publications and is a board member of the American Heart Journal , Catheterization and Cardiovascular Interventions and Cardiovascular Business . He is widely sought after as guest lecturer on both the national and international level.

Key members of NeoStem's executive management team, including Chairman and CEO, Robin Smith, MD, MBA, and Chief Medical Officer, Douglas Losordo, MD, will also be in attendance to answer questions regarding the Company and the released data.

The live webcast of the event will be available at http://www.neostem.com/investors/investor-events . The event can also be accessed by calling 1-855-235-8282 and providing Conference ID 40994522.

About NeoStem's Ischemic Repair Program

NeoStem is developing therapies to address ischemia through its Ischemic Repair Program (the Program), using CD34 cell technology. Ischemia occurs when the supply of oxygenated blood in the body is restricted. The Company's therapeutics seek to reverse this restriction through the development and formation of new blood vessels. The Program's lead product candidate is NBS10, a chemotactic hematopoietic stem cell product comprised of autologous bone marrow derived CD34/CXCR4 cells selected to treat damaged heart muscle following AMI (or heart attack). NBS10 is thought to work by increasing microvascular blood flow in the heart muscle via the development and formation of new blood vessels, thereby reversing the restriction of blood supply caused by a heart attack and rescuing at-risk cardiac tissue from eventual cell death.

About the PreSERVE AMI Clinical Trial

PreSERVE AMI is a randomized, double-blind, placebo-controlled clinical trial of intracoronary infusion of autologous CD34 cells in patients with left ventricular dysfunction post-ST elevation myocardial infarction (STEMI). The trial included 161 subjects at 60 sites in the United States, randomized 1:1 between treatment and placebo arms. Eligible patients presented with acute STEMI, had successful stenting of the infarct-related artery and had left ventricular dysfunction 4 days after AMI. Primary endpoints include occurrence of SAEs and MACE (defined as cardiovascular death, re-infarction, heart failure hospitalization, and coronary revascularization) through 3 year follow-up, occurrence of SAEs through 3 year follow-up, and 6-month change in myocardial perfusion (RTSS) measured quantitatively by gated SPECT myocardial perfusion imaging. Other endpoints include cardiovascular magnetic imaging resonance (CMR) to measure left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), left ventricular end-systolic diameter (LVEDV), regional myocardial strain, infarct/peri-infarct regional wall motion abnormalities and infarct size (baseline and six months) and quality of life measures (KCCQ and SAQ). While all 6 month data has been collected, it is subject to ongoing analysis, and results reported at this time, although promising, are preliminary. There can be no assurance that further analysis may not reveal negative, or less promising, results.

About NeoStem, Inc.

NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Targeted Immunotherapy Program, Ischemic Repair Program (including NBS10 for AMI), Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company's contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 13, 2014, the Company's Current Report on Form 8-K filed with the SEC on May 8, 2014 and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control.

Investor Contact: LifeSci Advisors, LLC Hans Vitzthum Managing Director Phone: +1-212-915-2568 Email: Media Contact: NeoStem, Inc. Eric Powers Manager of Communications and Marketing Phone: +1-212-584-4173 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 0

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 141

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
Hyundai’s Third SUV Crown Matters Beyond the Trophy

Updated Category News Views 0

A Three-Year Streak Is Not Just Decorative Three straight SUV-brand wins can make even a cynical car watcher pause. Hyundai has been named U.S. News & World Report’s 2027 Best SUV Brand after editors assessed vehicles from 39 brands, and that is a useful bit of outside validation in a segment where nearly everybody is throwing sheet metal, screens, and marketing dollars...

Continue Reading
NextPatient’s KLAS Marks Signal Specialty Workflow Fit

Updated Category News Views 79

A 93.3 score in healthcare software deserves a second look. Not a victory lap, not a drumroll—just a serious look at whether the product is solving an annoying, expensive operational problem for specialty practices. NextPatient’s recognition in the 2026 KLAS Emerging Solutions Top 20 Report lands in that category. The company placed in the top five for improving...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 131

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Rehab Equipment Growth Meets a Brutal Access Gap

Updated Category News Views 151

Rehabilitation demand is piling up faster than the equipment can reach people. That is the uncomfortable fact sitting beneath Wissen Research's forecast for a global rehabilitation equipment market rising from $19.1 billion in 2026 to $25.8 billion by 2031, a 6.2% annual growth rate. It is a respectable expansion story, not some rocket-ship fairy tale. More important, it...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 30

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 90

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
Dutch Solar Homes Face a 2027 Net Metering Reset Ahead

Updated Category News Views 24

A policy switch buried in a Dutch calendar is about to rearrange millions of kitchen-table energy calculations. On 1 January 2027, the Netherlands ends net metering, or salderingsregeling, and households with solar panels will no longer offset exported power against electricity bought from the grid. That is not some abstract regulatory footnote. It changes the value of...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 190

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading

Top 5 Most Recently Viewed Articles

DallasNews Shareholders Urged to Support Merger Deal with Hearst

Updated Category News Views 101

Overview of the DallasNews and Hearst Merger DallasNews Corporation, the parent company of The Dallas Morning News, has proposed a significant merger with Hearst, a prominent media organization. This merger offers an enticing cash value of $15.00 per share, bringing impressive benefits to shareholders. Recently, Glass Lewis, an independent proxy advisory firm, recommended...

Continue Reading
GitLab Director Karen Blasing's Recent Stock Transactions Explained

Updated Category News Views 154

Analyzing the Recent Insider Trading at GitLab GitLab Inc. (NASDAQ:GTLB) has recently drawn the attention of investors and market analysts due to stock transactions made by its director, Karen Blasing. A recent filing with the U.S. Securities and Exchange Commission revealed that Blasing sold a considerable amount of her stock holdings, totaling more than $173,000....

Continue Reading
Avenue Living's Strategic $350 Million Debenture Offering

Updated Category News Views 202

Avenue Living Announces $350 Million Senior Unsecured Debenture Offering Avenue Living (2014) LP has recently announced a significant financial move with a $350 million offering of Series B senior unsecured debentures. This opportunity is set to be priced at par and is due by September 25, 2028, indicating a long-term strategy for the company’s financing needs. Details...

Continue Reading
Fagron Reports Strong Financial Growth with Strategic Outlook

Updated Category News Views 349

Fagron's Remarkable Financial Performance Fagron, a global leader in pharmaceutical compounding, recently showcased its impressive results for the period ending December 31, 2024. The company’s financial achievements highlight significant growth across various sectors and regions in the pharmaceutical industry, reinforcing its commitment to excellence and innovation....

Continue Reading
Dizal's Sunvozertinib Receives Breakthrough Therapy Designation

Updated Category News Views 444

Dizal's Sunvozertinib Achieves Breakthrough Therapy Designation Dizal, a biopharmaceutical company dedicated to developing innovative cancer and immunological therapies, recently announced an important milestone. The Center for Drug Evaluation of China's National Medical Products Administration has granted Breakthrough Therapy Designation for sunvozertinib, aimed at...

Continue Reading